We investigated the effects of secondary prophylactic administration of G-CSF and the risk factors of the recurrent FN, grade 4 neutropenia, and RDI < 85% in Korean patients with breast cancer who received AC-based chemotherapy. This evidence concerns the gene CSF3 and breast cancer.